GlassScriptPhysician profile
Timothy J Dunn
NPI 1669523445
$39,107.98
in general payments reported to CMS, 2019-2025
78 companies · $6,134 in 2025
The $6,134 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,493 · 2020: $7,270 · 2021: $6,144 · 2022: $4,353 · 2023: $4,524 · 2024: $5,190 · 2025: $6,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $300 · Education: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,305.15 |
| Consulting Fee | $300.00 |
| Education | $242.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,331.46 | 2020 | |
| Emd Serono, INC. | $3,213.19 | 2019-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $3,122.66 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Eisai INC. | $2,324.42 | 2019-2025 | |
| Biogen, INC. | $2,252.01 | 2019-2025 | Tysabri, Vumerity, Plegridy |
| Abbvie INC. | $2,237.72 | 2021-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $2,213.38 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| E.R. Squibb & Sons, L.L.C. | $2,022.58 | 2020-2025 | Zeposia |
| Celgene Corporation | $1,487.27 | 2019-2025 | Zeposia |
| Lilly USA, LLC | $1,125.41 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Amgen INC. | $1,079.39 | 2019-2025 | Uplizna, Aimovig |
| Sk Life Science, INC. | $924.98 | 2020-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $852.88 | 2019-2024 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $850.90 | 2019-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $739.19 | 2020-2025 | Ingrezza, Ongentys |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.